Technical Analysis for ALZN - Alzamend Neuro, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 0.97 | 4.30% | 0.04 |
ALZN closed up 4.3 percent on Monday, March 18, 2024, on 60 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Bullish Engulfing | Bullish | 0.00% | |
Crossed Above 50 DMA | Bullish | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 50 DMA | Bearish | 4.30% | |
MACD Bearish Signal Line Cross | Bearish | 4.30% | |
NR7 | Range Contraction | 4.30% | |
Narrow Range Bar | Range Contraction | 4.30% |
Alert | Time |
---|---|
Rose Above 20 DMA | about 12 hours ago |
60 Minute Opening Range Breakout | about 12 hours ago |
Rose Above Previous Day's High | about 12 hours ago |
Up 5% | about 12 hours ago |
Possible NR7 | about 13 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 01/03/2024
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Biology Medication Neuroscience Alzheimer's Disease Dementia Neurodegenerative Diseases Psychiatric Diagnosis Amyloidosis Neurodegeneration Preclinical Stage Biopharmaceutical Psychiatric Disorders Treatment Of Neurodegenerative Diseases Treatment Of Alzheimer's
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Biology Medication Neuroscience Alzheimer's Disease Dementia Neurodegenerative Diseases Psychiatric Diagnosis Amyloidosis Neurodegeneration Preclinical Stage Biopharmaceutical Psychiatric Disorders Treatment Of Neurodegenerative Diseases Treatment Of Alzheimer's
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.032 |
52 Week Low | 0.1132 |
Average Volume | 54,392 |
200-Day Moving Average | 0.70 |
50-Day Moving Average | 0.94 |
20-Day Moving Average | 0.99 |
10-Day Moving Average | 1.08 |
Average True Range | 0.10 |
RSI (14) | 48.45 |
ADX | 24.87 |
+DI | 27.35 |
-DI | 18.03 |
Chandelier Exit (Long, 3 ATRs) | 1.00 |
Chandelier Exit (Short, 3 ATRs) | 1.14 |
Upper Bollinger Bands | 1.21 |
Lower Bollinger Band | 0.77 |
Percent B (%b) | 0.45 |
BandWidth | 43.87 |
MACD Line | 0.03 |
MACD Signal Line | 0.04 |
MACD Histogram | -0.0107 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.11 | ||||
Resistance 3 (R3) | 1.11 | 1.06 | 1.08 | ||
Resistance 2 (R2) | 1.06 | 1.03 | 1.06 | 1.07 | |
Resistance 1 (R1) | 1.02 | 1.01 | 1.04 | 1.02 | 1.07 |
Pivot Point | 0.97 | 0.97 | 0.99 | 0.97 | 0.97 |
Support 1 (S1) | 0.93 | 0.94 | 0.95 | 0.93 | 0.87 |
Support 2 (S2) | 0.88 | 0.92 | 0.88 | 0.87 | |
Support 3 (S3) | 0.84 | 0.88 | 0.86 | ||
Support 4 (S4) | 0.84 |